| Building on knowledge from preclinical models, translational pharmacology aims to reduce attrition in phase 2 clinical trials through enhanced understanding of human drug targets and drug candidates as well as improved prediction of drug exposure, dose and regimen. Quantitative protein LC-MS/MS plays an increasingly important role in this field for assessment of mechanism biomarkers as well as target biomarkers for biotherapeutic modalities, such as monoclonal antibodies. Furthermore, the LC-MS/MS technology is advancing be a useful 'biomeasurement' tool for determining key parameters that inform systems pharmacology, such as receptor and transporter expression in tissues. Relevant case studies will be presented. |
|
